Preclinical antimalarial combination study of M5717, a <em>Plasmodium falciparum</em> elongation factor 2 inhibitor, and pyronaridine, a hemozoin... (Publications)
Antimalarial drug resistance in the Plasmodium falciparum parasite poses a constant challenge for drug development. To mitigate this risk, new antimalarial medicines should be developed as fixed-dose
Short term association between ozone and mortality: global two stage time series study in 406 locations in 20 countries (Publications)
OBJECTIVE: To assess short term mortality risks and excess mortality associated with exposure to ozone in several cities worldwide. DESIGN: Two stage time series analysis. SETTING: 406 cities in 20 co
Malaria elimination transmission and costing in the Asia-Pacific: developing an investment case (Publications)
Background: The Asia-Pacific region has made significant progress against malaria, reducing cases and deaths by over 50% between 2010 and 2015. These gains have been facilitated in part, by strong pol
Activity of novel oral formulations of albendazole and mebendazole against <em>Heligmosomoides polygyrus in vitro</em> and <em>in vivo</em> (Publications)
Albendazole (ABZ) and mebendazole (MBZ) are the two most commonly used drugs in the treatment of soil-transmitted helminths in humans but their performance is hampered by low solubility and physicoche
Dual plasmepsin-targeting antimalarial agents disrupt multiple stages of the malaria parasite life cycle (Publications)
Artemisin combination therapy (ACT) is the main treatment option for malaria, which is caused by the intracellular parasite Plasmodium. However, increased resistance to ACT highlights the importance o
